Associated Papers
Pharmacokinetic recall study of Estonian Biobank participants with novel genetic variants in CYP2C19 and CYP2D6.
Krebs K et al.
Npj Genomic Medicine, 2026
41549095 (PubMed )
Supplement: 41525_2025_549_MOESM2_ESM.xlsx › Supplementary_Data_8
Catalogue of Somatic Mutations in Cancer Database and Structural Modeling Analysis of CYP2D6 Mutations in Human Cancers.
Kuchinski K et al.
The Journal of Pharmacology and Experimental Therapeutics, 2024
Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib.
Zhang X et al.
Ebiomedicine, 2024
39368455 (PubMed )
Supplement: mmc2.xlsx › Sheet1
The variation landscape of CYP2D6 in a multi-ethnic Asian population.
Maulana Y et al.
Scientific Reports, 2024
ACE Phenotyping in Human Blood and Tissues: Revelation of ACE Outliers and Sex Differences in ACE Sialylation.
Enyedi EE et al.
Biomedicines, 2024
38790902 (PubMed )
Supplement: biomedicines-12-00940-s001.zip › biomedicines-2930173-supplementary.pdf
Identification of the effects of pathogenic genetic variations of human CYP2C9 and CYP2D6: an in silico approach.
Avsar O
Nucleosides, Nucleotides & Nucleic Acids, 2024
Pharmacogenomic profile of actionable molecular variants related to drugs commonly used in anesthesia: WES analysis reveals new mutations.
Parada-Márquez JF et al.
Frontiers in Pharmacology, 2023
37021041 (PubMed )
Supplement: Table2.xlsx › Hoja1
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y et al.
The Pharmacogenomics Journal, 2022
36068297 (PubMed )
Supplement: 41397_2022_288_MOESM4_ESM.xlsx › Sheet1
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).
Matic M et al.
European Journal of Human Genetics : Ejhg, 2022
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
35846994 (PubMed )
Supplement: Table3.xlsx › Hoja1
Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
Shrestha R et al.
Cancer Research, 2021
33441310 (PubMed )
Supplement: can-20-2222_supplemental_st1-st14_suppst1-st14.xlsx › S3
Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multi-Ethnic Allele and Copy Number Variant Detection.
Scott SA et al.
Clinical and Translational Science, 2021
32931151 (PubMed )
Supplement: CTS-14-204-s001.xlsx › Table_S1
Identification of Novel CDH23 Variants Causing Moderate to Profound Progressive Nonsyndromic Hearing Loss.
Ramzan K et al.
Genes, 2020
33316915 (PubMed )
Supplement: genes-11-01474-s001.pdf
Assessing the capability of massively parallel sequencing for opportunistic pharmacogenetic screening.
Ng D et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017
27537706 (PubMed )
Supplement: NIHMS802548-supplement-Table_S4.pdf
Select a paper to view details